RRMM-Relapsed or Refractory Multiple Myeloma
Showing 1 - 25 of >10,000
Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis Trial (SAR445514)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- Amyloid Light-chain Amyloidosis
- (no location specified)
Apr 20, 2023
Patients With Relapsed/Refractory Multiple Myeloma
Not yet recruiting
- Relapsed and Refractory Multiple Myeloma (RRMM)
- Non-Interventional
- (no location specified)
Dec 21, 2022
Relapsed/Refractory Multiple Myeloma Trial (Isatuximab, Carfilzomib, Dexamethasone)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- Isatuximab
- +3 more
- (no location specified)
Feb 3, 2023
Relapsed/Refractory Multiple Myeloma Trial in Philadelphia (Cevostamab)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
-
Philadelphia, PennsylvaniaHospital of the University of Pennsylvania
Apr 7, 2023
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Carfilzomib, Cyclophosphamide, Dexamethasone)
Not yet recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Carfilzomib
- +2 more
- (no location specified)
Jun 8, 2023
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM) Trial run by the
Not yet recruiting
- Multiple Myeloma
- +2 more
- 18F-fluciclovine injection
- 18F-FDG PET/CT
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Oct 31, 2023
Multiple Myeloma, Primary Plasma Cell Leukemia Trial in Shanghai (Experimental: CAR-T cells Infusion)
Not yet recruiting
- Multiple Myeloma
- Primary Plasma Cell Leukemia
- Experimental: CAR-T cells Infusion
-
Shanghai, ChinaShanghai Changzheng Hospital
Apr 20, 2023
RRMM, Other Plasma Cell Diseases Trial (LM-305, Dexamethasone)
Not yet recruiting
- RRMM
- Other Plasma Cell Diseases
- (no location specified)
Dec 1, 2022
Multiple Myeloma, Relapse, Refractory Trial in Chapel Hill, Winston-Salem, Columbus (Isatuximab, Pomalidomide, Dexamethasone)
Not yet recruiting
- Multiple Myeloma
- +4 more
- Isatuximab
- +2 more
-
Chapel Hill, North Carolina
- +2 more
Jun 9, 2023
Quality of Life in Relapsed and/or Refractory Multiple Myeloma
Active, not recruiting
- Multiple Myeloma
-
Morrisville, North CarolinaLocal Institution
May 12, 2022
Relapsed/Refractory Multiple Myeloma Trial (AMG 701)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- AMG 701
- (no location specified)
Jun 6, 2022
Relapsed or Refractory Multiple Myeloma Trial (Daratumumab, Pomalidomide)
Withdrawn
- Relapsed or Refractory Multiple Myeloma
- (no location specified)
Jan 26, 2023
Relapsed or Refractory Multiple Myeloma Trial in Canada, United States (mRNA-2736)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- mRNA-2736
-
Birmingham, Alabama
- +12 more
Jun 15, 2023
Relapsed/Refractory Multiple Myeloma Trial in Japan (ABBV-383)
Recruiting
- Relapsed/Refractory Multiple Myeloma
-
Kashiwa-shi, Chiba, Japan
- +5 more
Jan 25, 2023
Multiple Myeloma Trial in Shanghai (Selinexor, Thalidomide, Lenalidomide)
Recruiting
- Multiple Myeloma
- Selinexor
- +4 more
-
Shanghai, Shanghai, ChinaShanghai Changzheng Hospital
Mar 3, 2022
Multiple Myeloma Trial in Zhengzhou, Wuhan, Xi'an (Selinexor (80mg/d), Selinexor (100mg/d), Pegylated liposomal doxorubicin)
Recruiting
- Multiple Myeloma
- Selinexor (80mg/d)
- +4 more
-
Zhengzhou, Henan, China
- +4 more
Aug 16, 2022
Multiple Myeloma in Relapse, Refractory Multiple Myeloma Trial in Israel (ixazomib-pomalidomide-dexamethasone)
Recruiting
- Multiple Myeloma in Relapse
- Refractory Multiple Myeloma
-
Afula, Israel
- +7 more
Jul 10, 2022
Multiple Myeloma Trial in Beijing, Jiang Su Province (Belantamab mafodotin)
Completed
- Multiple Myeloma
- Belantamab mafodotin
-
Beijing, China
- +2 more
Feb 8, 2022
Plasma Cell Myeloma Trial in United States (isatuximab SAR650984, lenalidomide, dexamethasone)
Active, not recruiting
- Plasma Cell Myeloma
- isatuximab SAR650984
- +2 more
-
San Francisco, California
- +4 more
Jun 16, 2022
Multiple Myeloma Trial in United States (Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone)
Recruiting
- Multiple Myeloma
- Ruxolitinib Oral Tablet [Jakafi]
- +2 more
-
Alhambra, California
- +12 more
Apr 18, 2022
Multiple Myeloma Trial in Worldwide (isatuximab SAR650984 IV, pomalidomide, dexamethasone)
Active, not recruiting
- Multiple Myeloma
- isatuximab SAR650984 IV
- +4 more
-
Gilbert, Arizona
- +14 more
May 6, 2022
Relapsed and/or Refractory Multiple Myeloma (RRMM) Trial in United States (TAK-981, Mezagitamab, Daratumumab and
Recruiting
- Relapsed and/or Refractory Multiple Myeloma (RRMM)
- TAK-981
- +2 more
-
Scottsdale, Arizona
- +11 more
Jan 6, 2022